BridgeMD
New treatment option for Glioblastoma
Official title Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques
ClinicalTrials.gov ID: NCT06623565
What this study is testing
- What it's testing
- Rationale: Patients with IDH-wildtype glioblastoma or grade IV IDH-mutant astrocytoma have a very poor prognosis despite standard treatment consisting of surgery, radiotherapy, and chemotherapy. Diffuse infiltration of the brain by the tumor is thought to be one of the main causes of this therapy-resistance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years
- New clinical and radiological suspected diagnosis of IDH-wildtype glioblastoma or grade IV IDH-mutant astrocytoma
- Visible FET PET uptake in the tumor as assessed by the nuclear physician
- Indication for a surgical resection and adjuvant treatment according to the neuro oncology multidisciplinary meeting
- Eligible for a supramarginal resection according to two neurosurgeons in consensus
You likely can't join if
- Previous brain surgery or cranial radiotherapy
- No significant other brain pathology, in the opinion of the PI or designee, such as multiple sclerosis, neurodegenerative disease, stroke
- Tumor located infratentorially or in the spinal cord
- Lack of adequate social or family support needed for adherence to the further postoperative therapeutic regimen
- Pregnancy
See the full eligibility criteria
- Age ≥ 18 years
- New clinical and radiological suspected diagnosis of IDH-wildtype glioblastoma or grade IV IDH-mutant astrocytoma
- Visible FET PET uptake in the tumor as assessed by the nuclear physician
- Indication for a surgical resection and adjuvant treatment according to the neuro oncology multidisciplinary meeting
- Eligible for a supramarginal resection according to two neurosurgeons in consensus
- Karnofsky Performance Score (KPS) ≥ 70.
- Previous brain surgery or cranial radiotherapy
- No significant other brain pathology, in the opinion of the PI or designee, such as multiple sclerosis, neurodegenerative disease, stroke
- Tumor located infratentorially or in the spinal cord
- Lack of adequate social or family support needed for adherence to the further postoperative therapeutic regimen
- Pregnancy
The study team makes the final eligibility decision.
Where it's taking place
- Amsterdam, North Holland, Netherlands
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Amsterdam, North Holland, Netherlands. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.